The main efficacy and therapeutic effects of Telisotuzumab

Telisotuzumab (Telisotuzumab) is an innovative antibody drug that belongs to the category of antibody conjugate drugs (ADC), which specifically targets the c-Met receptor on the surface of tumor cells for precise attack. c-MetThe receptor is overexpressed in a variety of tumor cells, driving tumor growth, metastasis and drug resistance. Terituzumab binds to the c-Met receptor to accurately deliver cytotoxins, directly killing tumor cells while minimizing damage to normal cells.

Clinical studies have shown that terituzumab has significant efficacy in the treatment of various solid tumors, especially non-small cell lung cancer (NSCLC). For c-Met positive patients, the drug can effectively inhibit tumor progression and improve the patient's progression-free survival (PFS) and overall survival rate (OS). In addition, it has shown therapeutic potential in patients who have failed previous treatments, bringing new treatment options to patients with refractory tumors.

The mechanism of action of terituzumab allows it to not only target a single target, but also carry potent cytotoxic drugs into tumor cells to enhance its killing power. This dual effect of "targeting plus cytotoxicity" greatly improves the therapeutic effect while reducing the systemic side effects caused by traditional chemotherapy drugs. When patients receive treatment, the drug is more selective and relatively well tolerated.

In general, terituzumab, as a cutting-edge targeted anti-cancer drug, provides new hope for patients with c-Met positive solid tumors with its unique structure and mechanism of action. With more clinical trials and marketing promotion, the drug is expected to play a more important role in the field of precision tumor treatment and improve patients' quality of life and treatment prognosis.

Reference materials:https://www.drugs.com/